Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]
News [7834]
Articles [63]
Editorials [9]
Conferences [210]
elearning [49]
Intermittent treatment with vemurafenib may prevent lethal drug resistance in...
Dr Darrin Stuart - Novartis Institutes for Biomedical Research, Emeryville, CA...
Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma ( Dr Darrin Stuart - Novartis Institutes for Biomedical Research, Emeryville, CA, USA )
8 Apr 2013
Potential novel inhibitor to overcome drug resistance induced by RAF, MEK...
Dr Ahmed Samatar - Merck Research Laboratories, Boston, USA
Potential novel inhibitor to overcome drug resistance induced by RAF, MEK Inhibitors ( Dr Ahmed Samatar - Merck Research Laboratories, Boston, USA )
8 Apr 2013
Sapacitabine and seliciclib, antitumour activity in patients with incurable...
Dr Geoffrey Shapiro - Dana-Farber Cancer Institute, Boston, USA
Sapacitabine and seliciclib, antitumour activity in patients with incurable BRCA-deficient cancers ( Dr Geoffrey Shapiro - Dana-Farber Cancer Institute, Boston, USA )
8 Apr 2013
AKT inhibitor AZD5363 in patients with advanced solid tumours
Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom
AKT inhibitor AZD5363 in patients with advanced solid tumours ( Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom )
8 Apr 2013
Whole genome sequencing reveals underlying genetics of multiple myeloma
Dr Jonathan Keats - The Translational Genomics Research Institute (TGen)...
Whole genome sequencing reveals underlying genetics of multiple myeloma ( Dr Jonathan Keats - The Translational Genomics Research Institute (TGen), Phoenix, USA )
4 Apr 2013
TIVO 1 study shows tivozanib an option for renal cell carcinoma
Dr Robert Motzer - Memorial Sloan Kettering Cancer Centre, New York, USA
TIVO 1 study shows tivozanib an option for renal cell carcinoma ( Dr Robert Motzer - Memorial Sloan Kettering Cancer Centre, New York, USA )
25 Feb 2013
Prediction of relapse in stage I nonseminomatous germ cell tumors by CXCL12
Dr Duncan Gilbert - Sussex Cancer Centre, Brighton , UK
Prediction of relapse in stage I nonseminomatous germ cell tumors by CXCL12 ( Dr Duncan Gilbert - Sussex Cancer Centre, Brighton , UK )
25 Feb 2013
Clinical trials and laboratory research
Prof Jonathan Ledermann - University College London, UK
Clinical trials and laboratory research ( Prof Jonathan Ledermann - University College London, UK )
14 Feb 2013
Advances in multiple myeloma from ASH 2012
Prof Thierry Facon - Centre Hospitalier Universitaire, France
Advances in multiple myeloma from ASH 2012 ( Prof Thierry Facon - Centre Hospitalier Universitaire, France )
20 Dec 2012
Expert overview of hot news in lymphoma from ASH 2012 (2/2)
Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger
Expert overview of hot news in lymphoma from ASH 2012 (2/2) ( Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger )
20 Dec 2012
Expert overview of hot news in lymphoma from ASH 2012 (1/2)
Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger
Expert overview of hot news in lymphoma from ASH 2012 (1/2) ( Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger )
20 Dec 2012
Advances in treatments for haematologic malignancies from the Sarah Cannon...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (5/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation